


QARC – IMRT Benchmark Update

- 57 submitted
 - 31 QARC IMRT benchmarks
 - 20 Approved
 - 13 Not approved
 - 3 No measurements
 - 1 no patients treated
 - 6 planning inadequate :
 - 2 OAR too high
 - 4 PTV coverage inadequate
 - 3 dose verification questions
 - 24 RPC approved
 - 2 awaiting RPC results



QARC – ITC Method 1 Progress

- *Late Summer 2004*

Hardware acquired and installed

- *October- November, 2004*

Software configured

- *December, 2004*

Import of trial patient data at QARC

- *January 6, 2005*

Import (via ITC) and review of first actual patient data (on-treatment review)

- *January 14, 2005*

Specific institutions invited to submit data using Method 1 for COG medullo and high grade glioma protocols

QARC – ITC Method 1 Progress

Concentration on QARC's ability to import data

CD import provided

Templates for two COG protocols created

(ACNS0126 –High Grade Glioma & ACNS0331 Std. Risk Medullo)

Institutions identified and requested to submit
data using Method 1

priority assigned by participation in above protocols and prior
successful transmissions to ITC

RRT tool:

Used by TJF for real review of protocol patient
window/level defaults installed

QARC – ITC Method 1

Near-Future Developments

- QARC staff (Ken, Marcia, Jeff) competent in data Import
- Ftp capability setup for QARC
- Patient data import directly at QARC (not through ITC)
- Increase number of institutions submitting
- Increase protocols supported (ECOG & SWOG head and neck)
- Development of printing or screen capture for QARC documentation (beam geometry parameters if no recalculation)
- Prioritizing user-friendly requests (import and RRT)

ATC Future

Needs of the coop groups for RT


- Real-time response review
- PET/CT fusion review
- Verification of accounting for organ motion
- Correlation of toxicities with partial volume doses
 - From multiple studies from multiple groups
- QA centers links to core imaging centers

Current - Protocols

Group	Active/Open	Active/Total	In Development
ACOSOG	3	5	4
CALGB	14	18	3
COG	34	60	18
ECOG	8	17	6
PBTC	4	4	-
SWOG	7	8	8
Sanofi- Aventis	1	1	2


Total Active: 113

Current – Patient Accrual




Current - Patients

Interventional Reviews



Current – Patient Total



QARC Board of Directors

Dec. 2004 Meeting

ACOSOG - Eli Glatstein, M.D.

CALGB – Harvey Mamon, M.D.

COG - Carolyn Freeman, M.D.

Suzanne Wolden, M.D.

ECOG - Harry Quon, M.D.

PBTC - Larry Kun, M.D.

SWOG - Paul Okunieff, M.D.

At Large - Moody Wharam, M.D.

NCI Guest – Norman Coleman, M.D.

Some Comments from QARC's Board of Directors (Dec 2004)

Pertinent to ATC Activities

- Plan for ITC integration needs to be formalized. Recent interactions are laudable. Now there is concern that the interaction be clearly defined to assure continuity.
- Relationship of QARC to:
 - CaBig
 - ACRIN
- Address QA for:
 - RF Ablation
 - Radioimmunotherapy
 - PET/CT
- Further Development of:
 - Dicom RT Capability
 - Method 2